<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-154508</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Dual antiplatelet therapy and haemoglobin level: an observational study</dc:title>
<dc:description xml:lang="en">Introduction. To determine the degree of association between dual antiplatelet therapy (DAPT) (clopidogrel plus acetylsalicylic acid) and haemoglobin (Hb) in clinical practice. Material and methods. A retrospective longitudinal analysis was conducted on all patients on DAPT for at least 6 months. The required sample size was 63 patients. Hb value was determined before DAPT and at least 6 months after, as well as length of treatment, drugs, and diseases that might reduce the Hb. Changes in Hb after DAPT and the emergence or worsening of pre-existing anaemia was determined. Before and after Hb was compared using the t-test for paired samples. The occurrence of anaemia was considered dependent variable in a logistic regression analysis. Results. A total of 122 cases were included. There were 92 (75.4%) males, and the mean age was 74.5 (SD 9.9) years. DAPT duration was 19.3 (11.8) months. The pre-treatment Hb was 14.3 (1.4) g/dl and 12.8 (1.9) g/dl post-treatment. The prevalence of pre-DAPT anaemia was 9.1% (11 cases), and 45.9% post-treatment (56 cases). Comparison of means showed a decrease of 1.5g/dl (1.6) (95% CI; 1.2-1.8, P&lt;.001). Anaemia post-treatment was associated with concomitant causes of anaemia, bleeding in the follow-up, and inversely with pre-treatment Hb level. Conclusions. DAPT is associated with a decrease in Hb. Anaemia or worsening of previous anaemia appeared in about half of the subjects, and this effect was most likely in patients with bleeding in the follow-up and if other causes of anaemia were present (AU)</dc:description>
<dc:creator>Díaz-Grávalos, GJ</dc:creator>
<dc:creator>Quinteiro-Alonso, MP</dc:creator>
<dc:creator>González-Cao, M</dc:creator>
<dc:creator>Barreales-Cardín, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. Determinar el grado de asociación entre la terapia de antiagregación plaquetaria dual (TAAD) (clopidogrel y ácido acetilsalicílico) y el nivel de hemoglobina (Hb) en la práctica clínica. Material y métodos. Estudio retrospectivo. Se incluyeron todos los pacientes con TAAD durante al menos 6 meses, siendo el tamaño muestral necesario de 63 pacientes. Se determinó la Hb antes de la TAAD y el valor más próximo al cierre del estudio, la duración del tratamiento y las prescripciones o enfermedades que pudieran disminuir la Hb. Se calculó la variación de Hb tras TAAD y la aparición o empeoramiento de anemia previa. Se comparó la Hb previa y la posterior mediante prueba t para muestras apareadas. La aparición de anemia fue la variable dependiente en un análisis de regresión logística. Resultados. Se incluyeron 122 casos. Noventa y dos eran varones (75,4%), con una edad media de 74,5 (DE 9,9) años. La duración de la TAAD era de 19,3 (11,8) meses, siendo la Hb previa de 14,3 (1,4) y la posterior de 12,8 (1,9) g/dl. Había anemia pretratamiento en 11 casos (9,1%) y postratamiento en 56 (45,9%). La comparación de medias mostró un descenso de 1,5 (1,6) (IC95% 1,2-1,8; p&lt;0,001) g/dl, asociándose la anemia postratamiento a la edad, causas concomitantes de anemia, hemorragias en el seguimiento y, de forma inversa, al nivel de Hb pretratamiento. Conclusiones. La TAAD se asocia con un descenso de la Hb, apareciendo anemia o empeoramiento de la misma en cerca de la mitad de los sujetos, y siendo este efecto más probable en los pacientes con hemorragias en el seguimiento y en presencia de otras causas de anemia (AU)</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);42(5): 293-297, jul.-ago. 2016. tab</dc:source>
<dc:identifier>ibc-154508</dc:identifier>
<dc:title xml:lang="es">Antiagregación plaquetaria dual y nivel de hemoglobina: un estudio observacional</dc:title>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d27769^s22031</dc:subject>
<dc:subject>^d4419^s22039</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22965^s22002</dc:subject>
<dc:subject>^d755^s22012</dc:subject>
<dc:subject>^d755^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d11410^s22045</dc:subject>
<dc:subject>^d28630</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d3162^s22074</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d4419^s22074</dc:subject>
<dc:subject>^d3162^s22045</dc:subject>
<dc:subject>^d4419^s22045</dc:subject>
<dc:subject>^d50295^s22045</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d28609</dc:subject>
<dc:subject>^d22198^s22002</dc:subject>
<dc:subject>^d27951^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201608</dc:date>
</metadata>
</record>
</ibecs-document>
